Prolia (Denosumab) vs Evenity (Romosozumab): Long-Term Durability of Response

How Each Drug Works: Different Engines, Different Timelines

Denosumab and romosozumab act on completely different molecular targets, and that distinction drives every durability question downstream.

Denosumab binds RANK-L, the cytokine that activates osteoclasts. Without RANK-L signaling, osteoclast differentiation stops and bone resorption falls sharply within days of each injection. The effect is entirely dose-interval dependent: bone turnover markers rebound toward baseline within weeks of a missed injection, and BMD may start declining within three to six months of a delayed dose.

Romosozumab neutralizes sclerostin, a glycoprotein secreted by osteocytes that ordinarily brakes bone formation. Blocking sclerostin simultaneously increases osteoblast activity and suppresses osteoclast activity for a window of roughly six to nine months before the anabolic effect wanes. This dual action explains why romosozumab produces spine BMD gains nearly double those of denosumab in head-to-head comparisons, but only within its fixed 12-month window.

The Clinical Implication of Mechanism

Because denosumab's antiresorptive effect is reversible, durability is entirely contingent on uninterrupted dosing. Because romosozumab's anabolic window closes at 12 months regardless of further injections, the gains must be consolidated with a subsequent agent. Neither drug alone constitutes a complete long-term strategy for most patients.

FREEDOM and the Long-Term Denosumab Data

The FREEDOM trial enrolled 7,808 postmenopausal women with osteoporosis and followed them for 36 months. Denosumab 60 mg every six months reduced new vertebral fracture risk by 68% relative to placebo (RR 0.32, 95% CI 0.26 to 0.41, P<0.001) and hip fracture risk by 40% (RR 0.60, 95% CI 0.37 to 0.97, P=0.04) [1].

The FREEDOM Extension followed participants for up to 10 years of continuous denosumab exposure. BMD at the lumbar spine continued rising throughout: a mean gain of 21.7% from baseline at year 10 compared to the 9.2% gain seen at year 3 in the original trial [2]. Nonvertebral fracture rates in the long-term extension group remained low and did not increase with duration of therapy.

What Happens When Denosumab Stops

That durability has a sharp boundary. A 2017 analysis published in the Journal of Bone and Mineral Research identified a pattern of multiple vertebral fractures occurring within 12 to 18 months of denosumab discontinuation, affecting patients who had no prior vertebral fractures [3]. The proposed mechanism is a post-denosumab rebound in bone resorption that transiently overshoots pre-treatment levels. Estimates suggest approximately 1 in 8 patients who discontinue denosumab without bridging therapy experiences a new vertebral fracture within two years.

Prescribers and patients must treat denosumab as a therapy that requires either perpetual continuation or a carefully planned exit strategy using bisphosphonates. The American Society for Bone and Mineral Research (ASBMR) published a task-force report in 2016 addressing this explicitly, noting that "patients who wish to discontinue denosumab should receive sequential antiresorptive therapy to prevent rapid bone loss" [3].

Denosumab Beyond 10 Years

Fewer than 200 patients have 10-plus-year exposure data. Cortical BMD at the hip shows continued, though slower, gains out to year 10. Osteonecrosis of the jaw and atypical femoral fractures remain rare at extended durations: the FREEDOM Extension reported rates of 0.1% and 0.03% per patient-year, respectively, in line with other antiresorptive agents [2].

ARCH and the Romosozumab Head-to-Head Data

The ARCH trial assigned 4,093 postmenopausal women with osteoporosis and either a prior fragility fracture or very low T-score to romosozumab 210 mg monthly for 12 months followed by alendronate, versus alendronate alone for 24 months [4]. At 24 months, the romosozumab-to-alendronate sequence reduced new vertebral fractures by 48% relative to alendronate alone (RR 0.52, 95% CI 0.40 to 0.66, P<0.001), clinical fractures by 27%, and hip fractures by 38%.

The FRAME trial, which compared romosozumab to placebo for 12 months and then transitioned all participants to denosumab, showed 73% reduction in new vertebral fractures at 12 months [5]. After the romosozumab group crossed over to denosumab, the fracture advantage persisted through 24 months, with nonvertebral fracture rates also diverging in favor of the romosozumab-first group.

Why the Anabolic Window Matters

The spine BMD gain of +13.3% at 12 months seen in ARCH's romosozumab arm has not been replicated by any single antiresorptive agent alone at the same timepoint. For a patient with a T-score of negative 3.5 and a recent vertebral fracture, closing that structural deficit rapidly may prevent the next fracture before slower-acting agents could.

The flip side: once the 12-month course ends, romosozumab's effect disappears without consolidation. BMD at the spine fell approximately 5 to 7 percentage points within 12 months in FRAME participants who received no follow-on therapy, erasing roughly half the gain made during the anabolic phase.

Cardiovascular Safety Signal

ARCH also produced the cardiovascular finding that prompted the FDA black-box warning. Serious cardiovascular events (MI, stroke, cardiovascular death) occurred in 2.5% of romosozumab patients versus 1.9% of alendronate patients over 24 months (P=0.05) [4]. Whether this reflects a drug-specific harm or a protective bisphosphonate effect in the comparator arm remains debated, but the FDA label states clearly that romosozumab should not be prescribed within 12 months of an MI or stroke.

Head-to-Head BMD Comparison: What the Numbers Actually Show

No randomized trial has directly compared denosumab and romosozumab using fracture endpoints as a primary outcome. The best available indirect comparison comes from the ARCH data and the FREEDOM Extension.

| Endpoint | Denosumab (FREEDOM, 36 mo) | Romosozumab (ARCH, 12 mo) | |---|---|---| | Lumbar spine BMD gain | +9.1% | +13.3% | | Total hip BMD gain | +4.0% | +6.2% | | New vertebral Fx reduction vs. Comparator | 68% vs. Placebo | 48% vs. Alendronate (24 mo) | | Hip Fx reduction vs. Comparator | 40% vs. Placebo | 38% vs. Alendronate (24 mo) | | Duration of effect | Continues with each injection | Maximal at 12 months, requires consolidation |

Over 10 years of continuous denosumab, the cumulative spine BMD gain (+21.7%) surpasses the peak romosozumab gain at 12 months. The strategic question is not which drug is stronger per milligram, but which sequence closes fracture risk fastest and sustains it longest.

Sequencing Strategy: Building a 5-to-10-Year Plan

The 2020 AACE/ACE Clinical Practice Guidelines for Diagnosis and Treatment of Postmenopausal Osteoporosis stratify patients into high-risk and very-high-risk categories. For very-high-risk patients (T-score <-3.0, prior hip or vertebral fracture, or FRAX 10-year major osteoporotic fracture probability above 30%), the guidelines recommend initiating an anabolic agent before an antiresorptive [6].

A practical three-phase framework for a newly diagnosed very-high-risk patient:

Phase 1 (Months 1 to 12): Romosozumab Complete all 12 monthly injections without interruption. Target a spine BMD gain of 10% or more before transitioning. Obtain a DXA at the end of month 12.

Phase 2 (Month 13 onward): Antiresorptive consolidation The FRAME data and the ARCH data both support transitioning directly to either denosumab 60 mg every six months or alendronate 70 mg weekly. Denosumab consolidation produced additional BMD gains of +3.2% at 24 months in the FRAME extension [5]. Alendronate is acceptable for patients who prefer oral therapy or who have cardiovascular history that increases the contextual benefit of a drug with independent CV data.

Phase 3 (Years 3 to 10+): Reassessment If the patient transitions to denosumab in Phase 2, monitor BMD every two years and plan for a drug holiday or bisphosphonate bridging if denosumab must stop. If alendronate is used, a formal drug-holiday reassessment at five years is standard per ASBMR guidance.

Should High-Risk (Not Very-High-Risk) Patients Start with Romosozumab?

For patients with T-scores between negative 2.5 and negative 3.0 without prior fracture, the calculus shifts. Denosumab alone reduced vertebral fracture risk by 68% in FREEDOM, a magnitude most clinicians find satisfactory for moderate fracture risk. Starting with romosozumab in this group exposes patients to the cardiovascular warning and a mandatory transition, adding complexity without proportionate fracture benefit for many individuals.

The Endocrine Society 2019 guideline notes that "the choice of initial therapy should weigh absolute fracture risk, comorbidities, patient preferences, and drug costs" [7]. That framing correctly places romosozumab as a tool calibrated for the highest-risk tier, not a universal first choice.

Switching from Prolia (Denosumab) to Evenity (Romosozumab)

This direction of switching, denosumab to romosozumab, is less studied and more complicated than the reverse.

Why Clinicians Consider It

Some patients started on denosumab before romosozumab was approved (FDA approval: April 2019). Others have been on denosumab for five or more years with satisfactory BMD but sustained high fracture risk due to falls, frailty, or concurrent glucocorticoid use. The hypothesis is that adding a romosozumab anabolic course on top of an established antiresorptive foundation could produce further BMD gains beyond what denosumab alone achieves.

What the Data Show

The STRUCTURE trial compared teriparatide (a different anabolic agent) after prior denosumab versus teriparatide after prior alendronate. Patients switching from denosumab to teriparatide showed cortical BMD loss at the hip despite gains at the spine, a pattern attributed to the removal of antiresorptive suppression [8]. Romosozumab has not been studied in an adequately powered trial specifically after denosumab, so the cortical response pattern remains uncertain in this context.

A 2021 post hoc analysis of FRAME subgroups suggested that patients with prior antiresorptive exposure (bisphosphonates) had attenuated anabolic responses to romosozumab at the hip, though spine responses remained strong. Whether prior denosumab similarly blunts hip cortical gains from romosozumab is not yet established [5].

The Safe Transition Protocol

If a clinician does plan a denosumab-to-romosozumab switch:

• Do not allow a gap longer than six months from the last denosumab injection before starting romosozumab. Denosumab's effect wanes at the six-month mark; any gap beyond that triggers rebound resorption before romosozumab's anabolic effect is established.
• Begin romosozumab within two to four weeks of the scheduled denosumab dose date.
• Confirm the patient has no MI or stroke within the prior 12 months (FDA boxed warning requirement).
• Plan antiresorptive consolidation at romosozumab month 12 to prevent the combined rebound of both agents stopping simultaneously.

Switching from Evenity (Romosozumab) to Prolia (Denosumab)

This is the most evidence-supported and guideline-endorsed transition in osteoporosis pharmacotherapy.

The FRAME trial built this transition into its design. After 12 months of romosozumab, all participants received denosumab. The romosozumab-first group maintained superior BMD and fracture outcomes through 24 months compared to the placebo-first group that also received denosumab from month 12 onward [5]. The BMD advantage established during the anabolic phase was preserved, not eroded, by denosumab consolidation.

Practically, the first denosumab injection should be administered within four weeks of the final (12th) romosozumab injection. Delaying the transition beyond eight weeks risks partial reversal of the anabolic gains as sclerostin suppression wears off and resorption rises.

Denosumab as Long-Term Maintenance After Romosozumab

Once a patient is on denosumab post-romosozumab, the same long-term considerations that apply to de novo denosumab users apply here. Every-six-month dosing must be maintained. If the patient eventually wishes to stop denosumab, a bisphosphonate bridge (zoledronic acid 5 mg IV or alendronate 70 mg weekly) should be started within the same visit or shortly after.

Special Populations and Practical Prescribing Notes

Glucocorticoid-Induced Osteoporosis

Denosumab has a specific indication for glucocorticoid-induced osteoporosis (GIOP) and has shown superiority over risedronate in spine BMD gains in this setting [9]. Romosozumab does not yet have an FDA indication for GIOP, though its anabolic mechanism could theoretically counteract glucocorticoid-mediated suppression of osteoblasts. Prescribers managing GIOP should default to denosumab or teriparatide as indicated agents unless enrolled in a clinical trial.

Male Osteoporosis

Denosumab is FDA-approved for men with osteoporosis at high fracture risk. Romosozumab received FDA approval for postmenopausal women only. Off-label use in men with very high fracture risk is practiced at some academic centers, but the evidence base is substantially thinner than in women.

Renal Impairment

Denosumab does not require dose adjustment for renal impairment and is preferred over bisphosphonates when eGFR is below 35 mL/min/1.73 m2. Romosozumab's renal safety profile is less characterized in severe CKD. The ARCH trial excluded patients with eGFR <30, and prescribing decisions in advanced CKD should be made in collaboration with nephrology.

Monitoring Parameters for Both Agents

Both drugs require baseline serum calcium (and correction of hypocalcemia before dosing), vitamin D sufficiency (25-OH-D above 20 ng/mL, ideally 30 to 50 ng/mL), and dental clearance review before the first injection.

During denosumab therapy: DXA every 1 to 2 years, serum calcium within 2 weeks of the first two injections in patients with renal impairment or vitamin D insufficiency, and annual review for jaw symptoms.

During romosozumab therapy: monthly injection adherence tracking (a missed injection means the next one should be given as soon as possible, but the 12-month course should not be extended beyond 14 months), ECG review or cardiology clearance for patients with borderline cardiovascular risk, and DXA at month 12 before transition.

FAQ